Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.7116
+0.0016 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
June 20, 2024
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 20, 2024
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
Via
InvestorPlace
“Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
November 15, 2023
Via
AB Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 19, 2024
Via
Benzinga
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 18, 2024
Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
May 31, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest to Participate in Upcoming Investor Conferences
May 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024
May 09, 2024
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 05, 2024
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Via
Benzinga
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 04, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023
March 19, 2024
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 19, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
March 14, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
March 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
February 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
January 30, 2024
Via
AB Newswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
November 14, 2023
Via
AB Newswire
Exposures
Product Safety
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 09, 2023
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.